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Abstract: Although the advent of inﬂ  iximab has changed the treatment paradigm and goals in 
inﬂ  ammatory bowel diseases (IBD), it does not provide a cure for IBD and recent evidence has 
demonstrated that the immunogenicity of this chimeric anti-TNF antibody is associated with 
secondary loss of response and intolerance. In ulcerative colitis (UC) the efﬁ  cacy of inﬂ  iximab 
was demonstrated in two large clinical trials, but long-term maintenance efﬁ  cacy data are lack-
ing. Novel biological agents have entered clinical development and pioneering trials have been 
reported in the last two years. For Crohn’s disease (CD) two anti-TNF agents, the fully human 
IgG1 anti-TNF monoclonal adalimumab and the humanized pegylated Fab-fragment certoli-
zumab-pegol and the humanized anti α4 integrin IgG4 antibody both have demonstrated efﬁ  cacy 
as maintenance agents. Adalimumab has been approved to treat active rheumatoid arthritis, 
psoriatric arthritis, and ankylosing spondylitis, and recently moderate-to-severe luminal CD 
has been added as an indication for this agent both by the FDA and EMEA. Further evidence is 
needed to establish the therapeutic potential of adalimumab in ﬁ  stulizing CD and in UC. The 
beneﬁ  t to risk ratio of anti-TNF agents in refractory IBD is clearly positive and since most of 
the toxicity is class speciﬁ  c, adalimumab is expected to have a safety proﬁ  le similar to that of 
inﬂ  iximab except for adverse events related to infusions.
Keywords: inﬂ  ammatory bowel diseases, CD, UC, biological treatment, medical treatment, 
controlled trial
Introduction
Inﬂ  ammatory bowel diseases (IBD) are chronically relapsing intestinal inﬂ  ammatory 
conditions with a typical onset in young adulthood and with an unpredictable disease 
course, which may lead to debilitating complications (Podolsky et al 2002). Crohn’s 
disease (CD) and ulcerative colitis (UC) are the two main phenotypes of IBD. These 
chronic immune mediated disorders are characterized by abdominal symptoms (diar-
rhea, abdominal pain rectal bleeding) and systemic manifestations (arthralgias, fatigue, 
dermatologic, and biliary complications). The most pertinent difference between the 
two illnesses is the disease location. CD typically occurs in the terminal ileum (ter-
minal enteritis) and right-sided colon. However, lesions can appear anywhere in the 
gut and the disease frequently affects different parts of the intestine with skip areas of 
uninvolved mucosa (regional enteritis). UC, on the other hand, universally involves 
the rectum and extends over a variable distance in the colon. Two thirds of the patients 
have only left sided colonic disease with sparing of the right colon. Also, CD is a 
transmural disease leading to ﬁ  stulas and intestinal strictures, whereas UC affects 
only the colonic mucosa and submucosa. Patients with CD are usually diagnosed in 
puberty or young adulthood, which means that this disease is associated with a high 
psychological and socio-economic and burden. The diagnosis is based on the clinical 
presentation, on ﬁ  ndings at ileo-colonoscopy and at enteroclysis, and on histological 
ﬁ  ndings in mucosal biopsies. The initial course of CD and UC is notably unpredictable 
at diagnosis. Some patients have smoldering ileal disease with few symptoms until 
they develop a ﬁ  brotic stricture, but others have signs of severe systemic inﬂ  ammation 
and invalidating diarrhea with abdominal cramps necessitating an early aggressive Biologics: Targets & Therapy 2007:1(4) 356
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medical management. However, most patients (60%–70%) 
will eventually develop protracted disease needing immune-
suppressive agents and/or surgery (Beaugerie et al 2006). 
Complications include obstructive strictures and internal 
ﬁ  stulas leading to bowel resection and perianal ﬁ  stulizing 
disease with secondary loss of anal sphincter function. Sur-
gery is unavoidable in more than 50% of patients with CD, 
but given the rapid disease recurrence after a surgical bowel 
anastomosis and the risk of short bowel syndrome, conserva-
tive bowel-sparing surgery is the gold standard.
CD and UC are relatively infrequent with an estimated 
incidence of 5 in 100,000 in the US, Canada, Australia, and 
Northwestern Europe. Southern America, Southern Europe, 
and the developing world appear to have a much lower inci-
dence. However, since CD is a life-time illness, peak IBD 
prevalences of 1 in 250 have been reported in Scandinavia. 
At present most patients need to be treated long term (sev-
eral decades), which increases the importance of an optimal 
beneﬁ  t to risk ratio whatever treatment is applied.
The advent of the anti-tumor necrosis factor (TNF) agent 
inﬂ  iximab has dramatically changed our concept of treat-
ing refractory IBD, particularly CD. Although inﬂ  iximab 
has proven to induce clinical response and remission with 
rapid onset of mucosal healing, to spare steroids, to improve 
perianal disease, and to increase quality of life, there is a 
considerable unmet medical need in both CD and UC. More 
humanized anti-TNF agents are prime candidates to ﬁ  ll the 
gap. This review will focus on the therapeutic potential of the 
human anti-TNF antibody adalimumab in active CD.
Current treatment and unmet 
medical need
The paradigm of treatment in CD has been revolutionized by 
the introduction of two classes of drugs. The advent of cor-
ticosteroids 4 decades ago enabled physicians and surgeons 
to bring patients to full disease remission without symptoms. 
However, although corticosteroids are used universally in 
immune-mediated disorders, they are double-edged swords. 
Steroids have high efﬁ  cacy at inducing remission (up to 80% 
in steroids naïve patients) but the side effect proﬁ  le does not 
allow long-term treatment. Moreover, up to 20% of patients 
lose the response to steroids over time (Munkholm et al 1994). 
Therefore, the advent of the biological agent, inﬂ  iximab 
(Remicade®), a chimeric monoclonal anti-TNF inhibitor, 
again dramatically changed the paradigm of CD treatment. 
Even if inﬂ  iximab does not bring the propect of cure, and sur-
gery is still desperately needed for patients with ﬁ  brostenosis 
and uncontrolled inﬂ  ammatory or ﬁ  stulizing disease, this drug 
has accomplished many goals for a good medical therapy in 
IBD (Table 1). Indeed, data from numerous clinical trials 
and from clinical practice in large academical centers have 
demonstrated that inﬂ  iximab induces and maintains remission 
in luminal, inﬂ  ammatory disease and that the improvement 
enables tapering of steroids (Targan et al 1997; Hanauer et al 
2002). Moreover, repeated administration of inﬂ  iximab results 
in ﬁ  stula healing (as judged by the cessation of drainage from 
cutaneous oriﬁ  ces) and maintenance therapy results in durable 
ﬁ  stula healing (Present et al 1999; Sands et al 2004).
Although many of these goals can also be achieved with 
azathioprine and probably also with methotrexate, these 
immunomodulators are characterized by a slow onset of 
action, and therefore are only useful to maintain remission. 
Furthermore, virtually all clinical trials have convincingly 
shown that anti-TNF agents are efﬁ  cacious in most patients 
failing adequate courses of immunomodulators such as aza-
thioprine (Targan et al 1997; Present et al 1999; Hanauer 
et al 2002; Sands et al 2004).
In general 50%–70% of patients report clinical improve-
ment when treated with inﬂ  iximab and 40% achieve remis-
sion. However, being a chimeric antibody, inﬂ  iximab is not 
devoid of immunogenicity and this is most likely the main 
mechanism underlying secondary loss of response to inﬂ  ixi-
mab (Baert et al 2003). Antibodies to inﬂ  iximab (ATIs) are 
associated with acute and delayed hypersensitivity reactions 
and with secondary loss of response (Baert et al 2003; Farrell 
et al 2003). Several treatment strategies such as systematic 
maintenance therapy, concomitant immunosuppression, and 
prophylactic systemic steroids decrease the incidence of ATI 
formation (Baert et al 2003; Farrell et al 2003; Rutgeerts et al 
2004; Hanauer et al 2004). Even when the treatment is opti-
mized to avoid anti-drug antibodies either by administering 
the antibody in scheduled maintenance or by concomitant 
immunosuppressive therapy, preliminary reports indicate that 
40%–50% of patients need an adjustment in dose or treatment 
schedule to avoid intermittent symptoms and 20% of patients 
lose their response over time (Siemanowski et al 2006; 
Table 1 Treatment goals for state novel therapies in Crohn’s 
disease
•   Induction and maintenance of symptomatic remission in a high pro-
portion of patients
•  Induction of endoscopic mucosal healing
•   Induction and maintenance of ﬁ  stula healing in a high proportion of 
patients
•  Prevention of complications and surgery
•  Long-term highly beneﬁ  cial beneﬁ  t to risk ratioBiologics: Targets & Therapy 2007:1(4) 357
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Van Assche et al 2006). Also inﬂ  iximab is administered as a 
2-hour infusion which means that patients treated long term 
need to visit an infusion center regularly (Tables 2, 3).
Development of adalimumab
Adalimumab is a fully human IgG1 antibody and the ﬁ  rst of 
these new generation monoclonal antibodies to be approved in 
human medicine (Figure 1). Guided selection on phage display 
was used to construct the antibody by Knoll and Abbott with 
assistance from Cambridge antibody technology. Using the 
murine anti-TNF monoclonal Ab MAK195 as a template, the 
genes for the VL and VH variable regions of the antibody were 
paired to human DNA sequences of the immunoglobulin reper-
toire. The hybrid gene encodes monomeric proteins containing 
the antigen binding protein. The phage display technique was 
than applied to select for high afﬁ  nity variable regions and the 
afﬁ  nity was further increased in multiple “mix and match” steps 
of recombination, which closely resemble the biological process 
of afﬁ  nity maturation underlying the high speciﬁ  city of our adap-
tive immune system. As a ﬁ  nal step in development the variable 
regions were linked to human constant regions, and immortal-
ized Chinese hamster ovary (CHO) cells were than transfected 
with this complete expression vector to produce a fully human 
IgG1 monoclonal antibody with a molecular weight of 148 kDa 
(Salﬁ  eld et al 2000; Osbourn et al 2005). Hence, adalimumab, 
is devoid of murine amino acid sequences. However, fully 
human “designed” monoclonals can be different from naturally 
occurring immunoglobulines in amino acids sequences and in 
glycoprotein content, and the complex proteins may undergo 
structural changes in solution or in the human tissue. As a con-
sequence, they may be recognized as a “non-self” epitope by 
the human adaptive immune system and generate human anti 
human antibodies (HAHAs). In the case of adalimumab these 
HAHAs are referred to as anti adalimumab antibodies.
Efﬁ  cacy of adalimumab in IBD
Luminal CD
Adalimumab (Humira®, Abott) has been commercially 
available for the treatment of rheumatoid arthritis since 
Table 2 Unmet needs in medical therapy for IBD
Crohn’s disease
Secondary inﬂ  iximab failure due to intolerance or loss of response
Primary failure of inﬂ  iximab treatment
Medical conditions precluding inﬂ  iximab treatment
Ulcerative colitis
Primary and secondary failure of inﬂ  iximab therapy
Induction of remission in severe disease (alternative for colectomy)
Table 3 Inﬂ  ammatory pathways in IBD targeted by biological therapies
Target in   Compound  Molecular  Molecular  Company  Development
inﬂ  ammatory    target  structure    phasea
reaction
T-cell   Adalimumab  TNF  Human Ab  Abbott  approved
cytokines/inﬂ  ammatory   Certolizumab-  TNF  Humanized  UCB/Celltech  III
pathways pegol    Fab  fragment   
 Golimumab  TNF  Human  Ab  Centocor  I
  RDP-58  TNF and   Peptide  Procter and   II
   other      gamble/genzyme 
   cytokines     
  Semapimod  TNF   guanylhydrazone  Cytokine   stopped
   signaling    pharmasciences 
 Fontolizumab  IFNγ Humanized  Ab  PDL  biopharma  II
 Tocilizumab  IL-6  R  Humanized  Ab  Chugai/Roche  II
T-cell differentiation/  ABT-874  IL-12/23  Human Ab  Abbott  II
proliferation CNTO-1275  IL-12/23  Human  Ab  Centocor  II
 Visilizumab  CD-3  Humanized  Ab  PDL  Biopharma  II
Selective adhesion   Natalizumab  α4 integrins  Humanized Ab  CD  halted
molecules       
 683699  α4 integrins  Unspeciﬁ  edb GSK/Tanabe  halted
 alicaforsen  ICAM–1  Antisense   ISIS  stopped
Innate immunity  GM-CSF  unknown  Recombinant   Schering AG/  III
     protein  berlex 
ainformation on development phase is subject to change.
bno information available to the author.
Abbreviations: TNF, tumor necrosis factor; IFN, interferon; IL, interleukin; R, receptor; CD, Crohn’s disease; UC, ulcerative colitis; GM-CSF, granulocyte-macrophage colony 
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2002 and more recently for spondylarthropathy, psoriatric 
arthritis, and CD. Clinical efﬁ  cacy in CD is inferred from open 
label experience (Sandborn et al 2004; Youdim et al 2004; 
Hinojosa et al 2007), from data in several placebo-controlled 
trials (Hanauer et al 2006; Colombel et al 2007; Sandborn et al 
2007a, b), and from in vitro data on the induction of apoptosis 
(Shen et al 2005; Shen et al 2006) (Table 4, Figure 2).
Two open label trials assessed the therapeutic potential of 
adalimumab in patients with CD initially responding to inﬂ  ixi-
mab and who had lost response or had become intolerant to this 
antibody. Sandborn et al reported on a trial enrolling 24 patients, 
who were dosed with 80 mg adalimumab at week 0 and 40 mg 
2 weeks later (Sandborn et al 2004). The open label trial ran for 
12 weeks with doses of 40 mg every 2 weeks. Adalimumab was 
well tolerated by all patients regardless of previous reactions 
to inﬂ  iximab and efﬁ  cacy was suggested with 59% of patients 
having 70 point CD activity index (CDAI) drop response rates 
at week 12. After week 4 patients had the option of increasing 
stepping up to 40 mg of adalimumab weekly, and 79% (19/24) 
decreased the interval to once per week. Youdim et al (2004) 
reported on a smaller trial in only 7 inﬂ  iximab-intolerant 
patients using a similar dosing strategy (Sandborn et al 2004). 
Of these, 5 out of 7 had high titers of antibodies to inﬂ  iximab 
when they had stopped treatment with this antibody earlier in 
their disease course. Also, in this trial adalimumab was well 
tolerated with only injection site reactions. In one patient clear 
endoscopic and histologic healing of the colonic mucosa was 
demonstrated after 8 weeks in the trial.
In the Clinical Assessment of Adalimumab Safety and 
Efﬁ  cacy Studied as Induction therapy in CD (CLASSIC I), 
a 4-week multicenter, randomized, placebo-controlled dose-
ranging study the efﬁ  cacy of adalimumab in 299 patients 
with active luminal CD was demonstrated particularly at 
the highest dose level (remission 160 mg week 0 and 80 mg 
week 2 36%, placebo 12%) (Hanauer et al 2006). Response 
as deﬁ  ned by a decrease of at least 70 points in the CDAI was 
also signiﬁ  cantly increased at lower dose levels (adalimumab 
40/20 mg: 54%, 80/40 mg: 59% [p   0.05], 160/80 mg 59% 
[p   0.01], placebo 37%), but remission and improvement 
of at least 100 points in the CDAI was observed only at the 
highest dose level. Patients who had completed CLASSIC I, 
were eligible to enter CLASSIC II with open label induction 
(40 mg adalimumab every other week [eow] twice) and sub-
sequently at 4 weeks randomization of patients in remission 
Table 4 Randomized controlled trials with adalimumab in Crohn’s disease
Number of 
patients,
population
Design Dosing
schedule
Outcome for primary endpoint
Induction 
of remission
CLASSIC I 
(Colombel et al 
2007)
299
moderatlely to
severely active
CD
RCT
double blind
placebo controlled
Wk 0: adalimumab sc 40, 80, 
160 mg or placebo:
Wk 2: adalimumab sc 20, 40, 
80 mg or placebo
Wk 4: higher remission rates in 
160/80 mg. adalimumab group
36% vs 12 % (p   0.001)
GAIN (Sandborn 
et al 2007)
325
moderatlely to
severely active
CD. Inﬂ  iximab
loss of response
or intolerance
RCT
double blind
placebo controlled
Wk 0: adalimumab sc 160 mg 
or placebo:
Wk 2: adalimumab 80 mg or 
placebo
Wk 4: Higher remission rates in 
160/80 mg. adalimumab group
21% vs 14 % (p   0.001)
Maintenance
of remission
CLASSIC II (Shen 
et al 2006)
259 RCT
open label induction
followed by doubled blind, 
placebo controlled trial
Wk 4 remitters (55/259) 
randomized to adalimumab 
sc 40 mg eow or 40 ew, wk 4 
through wk 56.
Wk 56 remission higher in both adalim-
umab groups: 79% (eow)
83% (ew), 44% placebo (p   0.05)
CHARM (Sand-
born et al 2007)
854 RCT
Open label induction
followed by double-blind 
placebo controlled trial
Wk 4 randomization of 
responders + non-responders 
to adalimumab sc 40 mg eow 
or 40 eow wk 4 through 
wk 56.
Remission rates higher in 
randomized responders (499/854)
wk 26: 40% (eow), 47% (ew), 12% placebo 
(p   0.01); 
wk 56: 36% (eow), 41% (ew)
12% placebo (p   0.01)
Abbreviations: RCT, randomized controlled trial; eow, every other week; ew, every week.Biologics: Targets & Therapy 2007:1(4) 359
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(at weeks 0 and 4) to adalimumab 40 mg eow or weekly or 
to placebo for 56 weeks. A total of 276 patients chose to be 
enrolled, and 55 achieved remission and were randomized 
(Sandborn et al 2007b). Patients not in remission (n = 204) 
were offered open label adalimumab 40 mg eow. Patients 
in both the randomized and open label arm had the option 
of stepping up the dose in case of a relapse from placebo to 
adalimumab 40 mg eow or from eow adalimumab 40 mg to 
no change initially and every week later on. In the randomized 
arm, 1 year (week 56) remission rates were signiﬁ  cantly 
higher in both adalimumab groups (40 mg eow: 79%, 15/19, 
40 mg weekly: 83%, 15/18, p   0.05 for both compared with 
placebo 44%, 8/18). Patients with concomitant immunosup-
pressives use were not more likely to be in remission at week 
56. In the open label arm, 131 of the 204 patients completed 
treatment through week 56 and of the original group of 204, 
93 (46%) were in remission at that time point. Reason for 
discontinuation included adverse events (23/73), lack of 
efﬁ  cacy (18/73), and withdrawal of consent (14/73). Step up 
from eow to weekly adalimumab 40 mg occurred in 60/131 
(46%) patients at some point before week 56.
The open label induction (80 mg at week 0, and 40 mg 
at week 2) Crohn’s Trial of the Fully Human Antibody 
Adalimumab for Remission Maintenance (CHARM) ran-
domized clinical responders and non-responders to receive 
adalimumab 40 mg SC eow, 40 mg. weekly, or placebo 
for 56 weeks (Colombel et al 2007). Co-primary endpoints 
were the proportion of randomized responders who were in 
remission at both week 26 and week 56. Patients in the two 
adalimumab groups were more likely to be in remission 
after 6 months (week 26: adalimumab 40 mg eow 40% (n = 
172) and 47% (n = 157) vs 17% (n = 170) for placebo) and 
after 1 year (week 56: 36% and 41% vs 12% for placebo, 
p   0.001). Again, no evidence for an increased efﬁ  cacy of 
a higher dosage schedule with 40 mg adalimumab weekly 
was found in this trial. However, in patients without con-
comitant immunosuppresives the group treated weekly had 
50% (18/36) remission rates vs 33% (12/36) eow, but this 
difference was not signiﬁ  cant. Of note, among all randomized 
patients 35% withdrew before the end of treatment. Also, 
50% of all randomized patients (251/505) left the randomized 
double-blind cohort and received adalimumab 40 mg eow or 
weekly. Factors predictive of response were not found, but of 
note higher numeric values were observed for remission at 
week 56 in anti-TNF naïve patients (42% adalimumab 40 mg 
eow, 48% weekly) compared to those treated with anti-TNF 
agents before (31% adalimumab 40 mg eow, 34% weekly). 
Sustained clinical remission with full discontinuation of 
steroids (for at least 90 days) was achieved more often in 
patients with active treatment (adalimumab 40 mg 29% eow 
and 20% weekly, placebo 5%, p   0.001 and p   0.01).
Subsequently, the GAIN (Gauging Adalimumab Efﬁ  cacy 
in Inﬂ  iximab Nonresponders) trial was designed to assess the 
efﬁ  cacy and safety of adalimumab in the patient group with 
loss of response to or intolerance of inﬂ  iximab. This short-
term (4 weeks) induction-of-remission trial compared adali-
mumab 160 mg at week 0 and 80 mg at week 2 with placebo 
(Sandborn et al 2007a). A total of 325 moderately to severely 
ill CD patients were randomized. Of these 57% had stopped 
inﬂ  iximab for intolerance and 52% for loss of response (13% 
experienced both problems). At week 4 signiﬁ  cantly more 
patients in the adalimumab group achieved remission (21% 
vs 7%, delta 14%, p   0.001). Improvement of the CDAI by 
at least 70 and 100 points was also signiﬁ  cantly better with 
adalimumab than with placebo. For the 70 point or more 
improvement this was observed as early as 1 week from 
baseline after one dose of 160 mg adalimumab SC (35% vs 
21% for placebo, p   0.01) and for both endpoints at both 
week 2 and week 4. Parallel to what was seen in CLASSIC 
I the IBD-questionnaire (IBDQ, disease speciﬁ  c measure of 
quality of life) scores were signiﬁ  cantly higher in the actively 
treated group (p   0.001, 150 vs 139). Subgroup analysis of 
efﬁ  cacy results showed that only concomitant steroid therapy 
was associated with better efﬁ  cacy (p = 0.01). In contrast, 
neither intolerance of nor loss of response to inﬂ  iximab, nor 
the combination of both, nor the presence of ATIs determined 
the efﬁ  cacy of adalimumab in this trial. At this time the precise 
implication of the apparent synergistic effect of concomitant 
steroids (and not of immunosuppressives) is unclear.
Perianal ﬁ  stulizing CD
Enterocutaneous ﬁ  stulas, more particularly in the perianal 
region, are an invalidating complication of CD and notably 
refractory to non-biological therapy. Inﬂ  iximab has shown 
to be beneﬁ  cial both in induction and in maintenance of 
ﬁ  stula oriﬁ  ce closure. For adalimumab the evidence is 
limited to open label trial data and secondary endpoints 
from trials in luminal CD. In the open label trial reported 
by Sandborn et al (2004) 3/9 (33%) patients with draining 
ﬁ  stulas achieved closure of all draining oriﬁ  ces at week 12 
after treatment with adalimumab 80 mg and 40 mg eow 
or weekly thereafter. A Spanish open label collaborative 
trial in 50 patients who had lost their response to or had 
become intolerant of inﬂ  iximab enrolled 22 patients with 
ﬁ  stulizing disease (Hinojosa et al 2007). Patients were 
treated with adalimumab 160 mg sc at baseline and with Biologics: Targets & Therapy 2007:1(4) 360
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80 mg at week 2. Of these patients 23% (5/22) achieved 
cessation of drainage from all fistula orifices (fistula 
remission) and 41% (9/22) had 50% or more of the oriﬁ  ces 
closed (ﬁ  stula response) at week 4. In GAIN, which also 
speciﬁ  cally enrolled patients who had previously failed 
inﬂ  iximab, 45/325 patients had draining enterocutaneous or 
perianal ﬁ  stulas at baseline (Sandborn 2007a). In this trial 
the ﬁ  stula response and remission rates were lower and no 
signiﬁ  cant improvement over placebo was observed (ﬁ  stula 
remission: adalimumab 160/80 mg: 8%, 2/25; placebo 5%, 
1/20, NS). In CHARM, with open label induction and a 
long-term blinded maintenance arm, signiﬁ  cantly more 
patients in the combined adalimumab groups achieved 
ﬁ  stula remission (week 26 30%; week 56 33%) than in 
the placebo group (13% week 26 and week 56, p   0.05) 
(Colombel et al 2007). At present it is not possible to 
position adalimumab between other approved treatments 
for ﬁ  stulizing disease, in particular relative to inﬂ  iximab. 
Due to the conﬂ  icting results, a speciﬁ  c controlled trial 
with clinical and biological endpoints such as magnetic 
resonance imaging for patients with ﬁ  stulizing disease is 
warranted.
Ulcerative colitis
Data for UC are limited to one open-label trial conducted in 
France. Ten patients were treated with 160 mg of adalimumab 
sc followed by 80 mg after 2 weeks. At 4 weeks, only 4 out 
of 10 patients had improved and in patients with more severe 
colitis (6/10) no responses were noted (Peyrin-Biroulet et al 
2007). Controlled data in this indication are clearly needed.
Other anti-TNF agents in clinical 
development
CDP-870, certolizumab pegol (Cimzia®, UCB/Celltech) a 
humanized Fab antibody fragment to tumor necrosis factor 
linked to polyethylene glycol (PEG) for subcutaneous admin-
istration, suggested efﬁ  cacy in CD patients with elevated 
C-reactive protein at baseline ( 10 mg/L) in an initial ran-
domized trial (Schreiber et al 2005). In the two subsequent 
trials, Precise 2 with an open label induction phase and pla-
cebo controlled maintenance, and Precise 1 with a placebo 
arm for both induction and maintenance certolizumab pegol, 
was more efﬁ  cacious than placebo at maintaining clinical 
response and remission over 26 weeks of therapy (Sandborn 
et al 2007c) . However, in the Precise 1 trial certolizumab 
pegol failed to induce clinical remission and was of modest 
beneﬁ  t for the induction of clinical response (7%–11% delta 
over placebo) (Sandborn 2007c).
Centocor also developed a fully human anti-TNF 
antibody, golimumab (CNTO-148). Phase II trials in rheuma-
toid arthritis have been completed and phase I trials have been 
initiated for CD. Etanercept, a p75 TNF receptor construct, 
also marketed to treat rheumatoid arthritis, failed to show 
efﬁ  cacy in refractory CD and is no longer in development 
for this indication (Sandborn et al 2001). Also, the soluble 
p55 TNF receptor Onercept (Serono®) has been developed 
for the treatment of refractory CD. A phase II randomized 
control trial, however, failed to show clinical efﬁ  cacy and 
further development has been discontinued (Rutgeerts et al 
2006).
Small molecules targeting TNF and TNF receptor signal-
ling are being developed although they are at an early stage. 
These compounds are less selective than monoclonal antibod-
ies and generally have a pleiotropic mechanism of action.
RDP-58 is an oral decapeptide inhibiting TNF production, 
but the molecule is also an inhibitor of p38 MAP kinase and 
of IL-12 synthesis. Procter and Gamble initiated a phase II 
trial in Europe in patients with refractory CD and UC with 
this molecule. RDP-58 at 3 dose levels once daily for 28 days 
was not better than placebo at inducing clinical response in 
patients with CD (Travis et al 2003). Of note, the placebo 
response in this trial was high as has been reported in other 
recent CD trials.
Semapimod (CNI-1493) is an oral guanylhydrazone p 
38 MAP kinase and JNK kinase signaling inhibitor. These 
kinases are important intermediates in the signaling of TNF 
and other inﬂ  ammatory cytokines such as IL-1 and IFN-
gamma. A phase II uncontrolled pilot trial suggested clinical 
efﬁ  cacy (Hommes et al 2002), but a placebo-controlled trial 
failed to meet its endpoints. Moreover, safety concerns with 
peripheral thrombophlebitis and liver abnormalities led to 
the interruption of further development.
Safety
From experience with clinical trials and commercial use 
with adalimumab in rheumatology, it appears that the safety 
proﬁ  le of this compound is similar to that of inﬂ  iximab with 
a decrease in immunogenicity (maximum 3.8% in the CD 
trials and maximum 17% antibodies in patients without 
concomitant methotrexate in rheumatoid arthritis) (Bartelds 
et al 2007; Colombel et al 2007). The principal speciﬁ  c safety 
issues are discussed below.
Injection site reactions
These reactions are a common observation with the sc injec-
tion of proteins in solution. In the combined safety data Biologics: Targets & Therapy 2007:1(4) 361
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from the trials in CD recently reported in abstract form by 
Colombel et al (Colombel et al 2007). Injection-site-related 
adverse events were noted in 65/279 patients treated with 
adalimumab 40 mg eow and 49 out of 275 with weekly 
treatment. Of the placebo-treated patients, 21/279 reported 
injection related adverse events. This represents 42 and 30 
events per patient-year of follow up for the two adalimumab 
groups respectively, and 21/100 patient-year for placebo. 
Injection site reactions hardly ever led to discontinuation of 
the medication.
Serious infections
Anti-TNF agents such as adalimumab and inﬂ  iximab have 
immunomodulatory properties. Even if ex vivo experiments 
have shown that human lymphocyte function is not affected 
by inﬂ  iximab (Cornillie et al 2001), recent experience has 
revealed a limited but real risk of serious infections. For 
anti-TNF agents in general, serious infections with intracel-
lular organisms such as tuberculosis, listeriosis, and histo-
plasmosis have received most attention and it is considered 
a class effect of these agents (Keane et al 2001; Wallis et al 
2005; Listing et al 2005). TNF membrane expression signals 
replication of intracellular pathogens to patroling immune 
cells. Therefore, inhibiting the cytokine with an anti-TNF 
agent hinders adequate and early control of an emerging 
reactivation of these pathogens. Therefore, screening for 
latent tuberculosis should be performed prior to initiation of 
adalimumab therapy as for every other anti-TNF agent. The 
package inserts of adalimumab mention the risk of serious 
infections as a boxed warning and strongly advocates screen-
ing for latent tuberculosis prior to initiating the drug, but 
awareness of infectious disease in general should be a standard 
attitude of every clinician prescribing immuno-modulatory 
agents. An update of the safety data with adalimumab in CD 
clinical trials has been recently released in abstract from. 
In 1459 patients (1506 patient-years of exposure), serious 
adverse events were more likely to occur in placebo-treated 
than in adalimumab-treated patients, both for induction and 
maintenance (Colombel et al 2007). For serious infections 
no difference was found in blinded maintenance therapy 
between the placebo and the two (40 mg eow or weekly) 
adalimumab groups (serious infection rate: placebo 9/100 
patient-years, adalimumab 40 mg eow: 5/100 patient-years, 
adalimumab 40 mg/week: 4/100 patient-years). Of all 1459 
adalimumab-exposed patients, a combined 2% reported an 
opportunistic infections. Candidiasis was most prevalent, but 
3 cases of tuberculosis were documented (0.2%). Of note, 66% 
of these patients had been exposed for at least 1 year when 
the analysis was performed. As a reference, the cumulative 
safety data with adalimumab in 10,050 patients with rheu-
matoid arthritis enrolled in adalimumab clinical trials and 
representing 12,506 patient-years of exposure, showed that 
the rate of serious infections was 5.1/100 patient-years, and 
the incidence rate of tuberculosis was 0.27/100 patient-years 
(Schiff et al 2006). It should be noted that in rheumatoid 
arthritis and in CD, adalimumab is often used in combination 
with other immunosuppressive agents. Although there is no 
clear signal of an increased infection rate of anti-TNF agents 
combined with methotrexate or azathioprine, the large (more 
than 10,000 patient years as of August, 2005) TREAT cohort 
study, which follows North American patients started either 
on inﬂ  iximab or on alternative immunomodulatory treatment, 
revealed that the risk of serious infections in inﬂ  iximab-treated 
patients is mainly linked to concomitant use of systemic 
steroids (Lichtenstein et al 2006).
Immunogenicity
As discussed before, humanization of therapeutic antibodies 
diminishes but does not abolish the risk of anti-drug anti-
bodies (Hwang and Foote 2005). In clinical practice only 
antibodies that interfere with drug efﬁ  cacy (neutralizing anti-
bodies) or instigate adverse events really matter. In recently 
reported IBD trials, humanized antibodies, in which only the 
hypervariable or complimentarity determining regions are of 
murine origin, induced 8%–44% of human anti-human anti-
bodies (HAHA). The humanized and pegylated anti-TNF Fab 
fragment, certolizumab, induced HAHA in 12% of patients 
but short-term response at 12 weeks was not affected by the 
antibody status (Schreiber et al 2005). Data on induction 
of antibodies to adalimumab in CD are available from one 
trial only with long-term administration of the antibody. The 
induction trials (CLASSIC I and GAIN) with exposure lim-
ited to 4 weeks are less useful to assess the immunogenicity 
of adalimumab, and in CHARM antibody formation was not 
evaluated. In the open label induction CLASSIC-II trial 7/269 
(2.6%) patients tested positive for antibodies to adalimumab, 
all in the 185 patient group without concomitant immuno-
suppression (3.8%) (Sandborn et al 2007b). At the present 
time these data don’t allow to reach ﬁ  nal conclusions about 
the relevance of these antibodies for the clinical efﬁ  cacy 
of adalimumab. In the open label trial reported by Youdim 
et al (Youdim et al 2004) 79% and in the open label arm 
(Sandborn 2007b) of the CLASSIC-2 trial 46% of patients 
stepped up to once weekly dosing for an increase in symp-
toms. However, data on the correlation between the need for 
decrease in dosing interval and AAA or adalimumab serum Biologics: Targets & Therapy 2007:1(4) 362
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concentrations are not available at present. Also, in general, 
determining antibodies to adalimumab in the presence of 
measurable adalimumab serum concentrations is not reli-
able. In GAIN none of the 159 adalimumab-treated patients 
tested positive for antibodies to adalimumab at 4 weeks, but 
the median adalimumab serum level at that point was 12.2 
μg/mL, and most patients had measurable serum adalimumab 
levels. Again, as a reference, in all rheumatoid arthritis trials 
combined, the drug induced HAHA in 5% of patients and 
concomitant methotrexate was clearly protective (Weinblatt 
et al 2003; Anderson 2005).
Autoimmunity
Anti-TNF agents are known to induce anti-nuclear antibodies 
(ANAs). These antibodies are associated with adverse events 
such as arthralgias and dermatological problems. Also, anti-
TNF therapy has been associated with drug-induced lupus, 
almost always associated with the induction of anti-double 
stranded (ds) DNA antibodies. The chimeric monoclonal 
antibody, inﬂ  iximab has been reported to induced ANA in 
up to 56% of patients, with anti ds DNA in more than half of 
them (Vermeire et al 2003). For adalimumab, to the best of 
our knowledge, ANAs were only measured in the CLASSIC 
II trial. Of the 172 patients with measurements at baseline and 
56 weeks and no ANAs at baseline, 33 (19%) tested positive 
at their ﬁ  nal visits, and anti dsDNA Ab were observed in all 33 
patients at this time point (Sandborn et al 2007b). None of the 
patients developed novel clinical symptoms suggestive of auto-
immunity, but cases of drug-induced lupus have been reported 
in CD and rheumatoid arthritis (RA) trials with adalimumab.
Malignancy
The safety data accumulated with the use of anti-TNF agents 
in clinical trials and from cases reported in commercial use 
indicate that there is no clear increase over the background 
incidence of malignancies in general.
Non-Hodgkin’s lymphoma has been a particular concern 
in patients treated with immuno-modulators. The incidence 
of lymphoma in IBD patient cohorts has been variable (rela-
tive risk 1–31) probably due to the heterogeneity of patient 
populations. A recent report from a large cohort of Swedish 
CD and UC patients found a marginally increased risk of 
Figure 1 Humanization of therapeutic antibodies. In general the immunogenicity of therapeutic antibodies has decreased with advances in humanization. The efﬁ  cacy of an 
antibody is determined by afﬁ  nity, avidity, and antibody isotype. This is independent of the degree of humanization.
Abbreviations: CDR, complimentarity determining region;  V, variable region; H, heavy chain; L, light chain; C, constant region.
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lymphoma (standardized incidence ratio [SIR] 1.3) (Askling 
et al 2005). In patients with UC the risk of myeloid leuke-
mia (SIR 1.8) was increased while the lymphoma risk was 
identical to the control population. As in previous reports 
the lymphoma risk in CD was elevated only in the ﬁ  rst year 
after diagnosis and no trend of an increase in more recent 
sub-populations (with a presumably higher exposure to 
immunomodulators) was observed. In the cumulative safety 
experience with adalimumab in CD trials 16/1,459 patients 
(1.1%) developed a malignancy, including 1 lymphoma 
(0.07/100 patient-years) (Colombel et al 2007). In the rheu-
matoid arthritis clinical trials 15 lymphomas were seen after 
12,506 patient-years of exposure (0.12/100 patient-years) 
resulting in a standardized incidence rate (SIR) of 3.19, which 
is comparable to that of a patient population not treated with 
biological (Schiff et al 2006). A recent report from the US 
national database for rheumatic diseases in 19,562 patients 
with RA (55% treated with an anti-TNF agent) represent-
ing 89,710 patients-years of follow up indicated that there 
was no increase in lympoma risk attributable to biological 
therapy in general or adalimumab speciﬁ  cally (OR 4.5, 95% 
CI 0.9–23.1) (Wolfe and Michaud 2007). Since RA sever-
ity is linked to the lymphoma risk and patients with more 
severe disease are more likely to receive biological therapy, 
the analysis was corrected for disease severity. On the other 
hand, a meta-analysis also using statistical modeling of data 
from clinical trials and reports from large patients cohorts in 
rheumatoid arthritis has suggested that inﬂ  iximab and adali-
mumab at higher doses ( 40 mg eow for adalimumab) is 
associated with an increased malignancy risk (Bongartz et al 
2006). The total body of evidence warrants careful follow-up 
of patients treated with biological agents, but in general do 
not show a clear increased risk for developing lymphoma or 
other malignancies.
Adalimumab: place in therapy
Both the FDA and the European agency EMEA approved of 
the use of adalimumab (Humira®) in patients with moderate 
Figure 2 Remission rates compared to placebo in adalimumab clinical trials in Crohn’s disease.
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to severe (US) or severe (Europe) CD failing other standard 
therapies or who have become intolerant of inﬂ  iximab. The 
US label recommends using an induction dose of 160 mg at 
week 0 followed by 80 mg 2 weeks later and 40 mg eow in 
maintenance. The European label recommends an induction 
dose of 80 mg followed by 40 mg after 2 weeks, with the 
option of giving double the dose (160/80 mg) at these time 
points if a more rapid effect is needed for the patients. Also 
the European label demands concomitant steroid therapy 
when adalimumab is initiated, if steroid use is not contrain-
dicated. None of the biologicals or small molecule agents 
currently developed to treat CD have been tested in a com-
parative trial against inﬂ  iximab or other standard therapies. 
Although regulatory agencies favor active comparator trials 
for registration purposes, the complexity of double dummy 
trials with two IV agents and the recent move towards 
subcutaneous administration of therapeutic antibodies has 
hindered this process. Also, most patients entering clinical 
trials with biologicals are failing standard therapies such as 
corticosteroids and azathioprine. One open label randomized 
trial enrolling patients early on in their disease course favored 
“top down” inﬂ  iximab + azathioprine over “step up” steroids 
and later initiation of azathioprine for short-term steroid-
free remission and long-term endoscopic mucosal healing 
(Hommes et al 2006). Data on biological ﬁ  rst, top down 
strategies with adalimumab are not available. Given the 
lack of comparative trials with anti-TNF and other biologi-
cal agents in CD, deciding between ﬁ  rst- and second-line 
biologicals is tedious. Outcomes of phase II trials with novel 
anti-TNF therapies such as adalimumab and certolizumab 
can be hardly compared with historical pivotal inﬂ  iximab 
trials due to an unmistakable change in patient populations. 
Approximately half of the patients with CD currently entering 
clinical trials have lost their response or have become intol-
erant to inﬂ  iximab. This may work both ways to inﬂ  uence 
the outcome. Those patients may be enriched for the effect 
of anti-TNF agents or biologcals in general because they 
were initially responding. However, inﬂ  iximab refractory 
patients may also have developed a less inﬂ  ammatory disease 
phenotype with symptoms driven by bowel obstruction or 
by a disturbed motility. The latter hypothesis is supported 
by the fact that in the GAIN trial after 4 weeks only 21% of 
patients achieved remission with adalimumab 160/80/40 mg 
induction therapy (Sandborn et al 2007a).
The precise mechanism of action for biologicals in IBD 
also needs to be elucidated further. The relative role of T-cell 
apoptosis induction, considered crucial for the efﬁ  cacy of anti-
TNF agents in CD (Lugering et al 2001; ten Hove et al 2002; 
van den Brande et al 2003; Di Sabatino et al 2004), needs to be 
revisited in view of recent data of efﬁ  cacy with certolizumab, 
which does not induce apoptosis (Nesbitt et al 2007).
Subcutaneous administration may be preferred by many 
patients because it allows home-based care and abolishes 
the need for visits to an infusion unit, which will undoubt-
edly also affect the total drug cost. However, subcutaneous 
dosing of novel anti-TNF agents is generally more frequent 
than the inﬂ  iximab re-treatment schedule. Also, the regular 
visits of a patient to the infusion enable closer monitoring of 
compliance and adverse events, and this monitoring should 
not be neglected by physicians and patients alike.
Abbreviations
IBD, inﬂ  ammatory bowel diseases; IL, interleukin; Ig, 
immunoglobulin; TNF, tumor necrosis factor; CD, Crohn’s 
disease; UC, UC; IV, intravenous; SC, subcutaneous.
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